gene therapy targets defects in neuromuscular junction transmission

Myasthenia Alliance Australia is pleased to support and highlight organisations undertaking cutting edge research and development related to our mission. One such organisation is Amplo Biotechnology, whose AAV-Dok7 gene therapy targets defects in neuromuscular junction transmission.